Glaucoma Market Forecast 2034: USD 4,073 Million Market Size, 30+ Companies, and 15+ Emerging Therapies Shaping Growth, estimates DelveInsight

Major Glaucoma players include Allergan (AbbVie), Sun Pharma Advanced Research Company Limited, Santen Pharmaceutical Co., Ltd., Alcon, D. Western Therapeutics Institute (DWTI), Kowa Ltd., Senju Pharmaceuticals, Otsuka Pharmaceuticals, Bausch and Lomb, Novartis, Merck & Co., Aerie Pharmaceuticals, Nicox Ophthalmics, Sylentis, Envisia Therapeutics, Ocuphire Pharma, TearClear, Peregrine Ophthalmic, and others.
The Glaucoma Market across the seven major markets (7MM) - the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan - continues to demonstrate steady expansion, driven by increasing disease prevalence, aging populations, and a rapidly evolving treatment landscape. According to DelveInsight, the glaucoma market was valued at approximately USD 4,073 million in 2022 and is projected to witness substantial growth through 2034, supported by a strong pipeline of emerging therapies, advanced drug delivery technologies, and rising awareness around early diagnosis and treatment adherence.

Among the 7MM, the United States emerged as the dominant contributor, accounting for USD 2,571 million in 2022, reflecting higher diagnosis rates, broader access to advanced therapies, and faster adoption of innovative treatment modalities. In contrast, the United Kingdom represented the smallest share, with a market size of approximately USD 132 million, although increasing screening initiatives are expected to support gradual growth.

DelveInsight's latest report, "Glaucoma Market Insights, Epidemiology, and Market Forecast - 2034," delivers a comprehensive evaluation of the current and future glaucoma treatment ecosystem, including disease understanding, epidemiology trends, treatment algorithms, clinical trial activity, regulatory milestones, competitive dynamics, and market forecasts across the 7MM.

Explore detailed forecasts, pipeline updates, and patient analytics in the Glaucoma Market. Download Report Now - [https://www.delveinsight.com/report-store/glaucoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Understanding Glaucoma: A Progressive and Irreversible Eye Disorder

Glaucoma is a chronic, progressive group of optic neuropathies characterized by damage to the optic nerve, often - but not always - associated with elevated intraocular pressure (IOP). Frequently referred to as the "silent thief of sight," glaucoma is one of the leading causes of irreversible blindness globally due to its asymptomatic progression in early stages.

The disease encompasses multiple subtypes, including:

* Primary Open-Angle Glaucoma (POAG) - the most prevalent form, characterized by gradual IOP elevation and optic nerve damage
* Angle-Closure Glaucoma (ACG) - a medical emergency caused by sudden blockage of aqueous humor drainage
* Normal-Tension Glaucoma (NTG) - optic nerve damage despite normal IOP levels
* Congenital Glaucoma - a rare condition present at birth

Key risk factors include advancing age, family history, diabetes, hypertension, and ethnicity. Given the irreversible nature of vision loss, early detection, continuous monitoring, and long-term treatment compliance remain critical to preserving visual function.

Access comprehensive epidemiology and market breakdowns across the 7MM. Request Free Sample - [https://www.delveinsight.com/sample-request/glaucoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Glaucoma Epidemiology and Patient Burden Across the 7MM

DelveInsight's epidemiological assessment highlights a significant and growing patient population across the 7MM. In 2022, there were approximately 16.6 million total prevalent glaucoma cases, of which nearly 7 million diagnosed cases were attributed to open-angle glaucoma, underscoring its dominance within the disease spectrum.

The diagnosed patient pool is expected to expand considerably by 2034 due to:

* Aging populations globally
* Increasing prevalence of metabolic disorders such as diabetes
* Improved screening and diagnostic technologies
* Enhanced disease awareness among patients and physicians

Despite these advances, underdiagnosis remains a major challenge, particularly in early-stage disease, creating both a clinical and commercial opportunity for innovative diagnostic and therapeutic solutions.

Current Glaucoma Treatment Landscape and Marketed Therapies

The current glaucoma treatment paradigm focuses on reducing intraocular pressure to slow disease progression. Existing therapies include:

* Prostaglandin analogs
* Beta-blockers
* Carbonic anhydrase inhibitors
* Alpha-2 adrenergic agonists
* Fixed-dose combination therapies
* Adjunctive and supportive treatments

While these therapies are effective in lowering IOP, long-term treatment adherence remains suboptimal due to issues such as frequent dosing requirements, side effects, and patient forgetfulness - factors that have fueled demand for sustained-release and minimally invasive solutions.

Learn more about Glaucoma treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ [https://www.delveinsight.com/report-store/glaucoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Glaucoma Market Growth Drivers and Key Challenges

Glaucoma Market Drivers

* Rising global prevalence of glaucoma and ocular hypertension
* Increased screening and early diagnosis initiatives
* Technological advancements in drug delivery systems
* Growth of minimally invasive glaucoma surgery (MIGS)
* Strong regulatory support from agencies such as FDA, EMA, PMDA, and NICE

Glaucoma Market Barriers

* Asymptomatic early disease leading to delayed diagnosis
* High treatment costs and reimbursement limitations
* Long-term patient non-compliance
* Complex and time-intensive regulatory approval processes

Despite these challenges, pipeline innovations and strategic collaborations are expected to reshape the glaucoma market over the next decade.

Emerging Therapies Transforming the Glaucoma Market

The glaucoma pipeline is robust, with several late-stage and innovative therapies anticipated to enter the market between 2025 and 2034. Key emerging treatments include:

* iDose TR (Travoprost Intraocular Implant) - a long-acting implant offering sustained IOP control
* NCX-470 - a nitric oxide-donating prostaglandin analog with enhanced efficacy
* DURYSTA (Bimatoprost SR) - a sustained-release intracameral implant
* ROCKLATAN / ROCLANDA - fixed-dose combinations improving treatment outcomes
* TRS01 - targeting inflammation-driven glaucoma mechanisms

These therapies aim to reduce dosing frequency, improve adherence, and deliver consistent therapeutic outcomes, addressing critical unmet needs in glaucoma management.

Recent Glaucoma Clinical Trials and Regulatory Milestones

Glaucoma research has accelerated globally, with several landmark developments over the past two years:

* In October 2025, Avisi Technologies, Inc., an ophthalmic medical device company advancing novel, sight-saving technologies, announces that the US Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) submission for Avisi's glaucoma treatment device VisiPlate Registered .
* In September 2025, Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Abbreviated New Drug Application (ANDA) for bimatoprost ophthalmic solution 0.01% (2.5 mL, 5 mL and 7.5 mL). The product is the generic equivalent of LUMIGAN Registered (bimatoprost ophthalmic solution) 0.01%, whose design is a trademark of Allergan, Inc., an AbbVie company.
* In August 2025, Qlaris Bio Inc. launched a study to evaluate the safety and tolerability of QLS-111 0.015% compared to Timolol Maleate 0.5% PF ophthalmic solution in patients with normal-tension glaucoma (NTG). The trial's primary goal is to assess both ocular and systemic safety while determining how well patients tolerate QLS-111 versus the active control.
* In August 2025, Myra Vision, a Shifamed portfolio company, announced today that the U.S. Food and Drug Administration (FDA) has issued a conditional approval letter for its Investigational Device Exemption (IDE) application to initiate the ADAPT study. The prospective, nonrandomized, open-label trial will evaluate the safety and effectiveness of Myra's Calibreye Trademark Titratable Glaucoma Therapy Trademark (TGT) Surgical System in up to 70 refractory glaucoma patients with 12-month primary effectiveness endpoint.
* In April 2025, AbbVie released updates of a Prospective, Multicenter Clinical Study to Evaluate the Safety and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Subjects With Glaucoma
* In March 2025, Qlaris Bio, Inc. announced a Randomized, Active-controlled, Multi-site, Double-masked, Pilot Study to Evaluate the Safety and Tolerability of QLS-111 Versus Timolol Maleate Preservative Free 0.5% Ophthalmic Solution in Subjects with Normal Tension Glaucoma (NTG)
* In February 2025, Alcon announced the US Launch of Voyager DSLT, a first-of-its-kind treatment for glaucoma and ocular hypertension.
* In November 2024, MediPrint Registered Ophthalmics, a clinical-stage ophthalmic drug delivery company based in San Diego, revealed the results of its Phase 2b clinical trial for LL-BMT1. This trial utilized a novel 3D-printed, drug-eluting contact lens designed to deliver bimatoprost and hyaluronic acid for sustained treatment. The trial successfully met all Phase 2b endpoints. Dr. Ian Ben Gaddie presented these findings at the American Academy of Optometry's annual meeting in Indianapolis, emphasizing LL-BMT1's potential as an innovative solution for managing mild to moderate glaucoma while enhancing contact lens comfort and alleviating dry eye symptoms.
* In October 2024, At the American Academy of Ophthalmology (AAO) 2024 conference held in Chicago, Illinois, findings from a Phase II study evaluating the safety of Neurotech Pharmaceuticals' NT-501 encapsulated cell therapy, which secretes ciliary neurotrophic factor (CNTF), were presented. The results were shared by Alexandria M. Dominguez, MS, a research assistant at the Byers Eye Institute at Stanford University. The study indicated that the CNTF-secreting implants were well-tolerated by patients with primary open-angle glaucoma, with no severe adverse events reported. This therapy showed promising potential in managing intraocular pressure (IOP) and supporting retinal health, both of which are essential for effective glaucoma treatment.
* On February 2024, Laboratoires Thea announced a study for Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.
* On March 2024, Amneal Pharmaceuticals announced a Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint Comparing Generic Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN Registered (Bimatoprost Ophthalmic Solution) 0.01% in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes.

Learn about upcoming therapies, clinical trials, and market potential to guide your next investment or R&D initiative - [https://www.delveinsight.com/sample-request/glaucoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Glaucoma Competitive Landscape: Key Companies

The glaucoma market is highly competitive, featuring both established pharmaceutical leaders and emerging biotech innovators. Major players include:

Allergan (AbbVie), Sun Pharma Advanced Research Company Limited, Santen Pharmaceutical Co., Ltd., Alcon, D. Western Therapeutics Institute (DWTI), Kowa Ltd., Senju Pharmaceuticals, Otsuka Pharmaceuticals, Bausch and Lomb, Novartis, Merck & Co., Aerie Pharmaceuticals, Nicox Ophthalmics, Sylentis, Envisia Therapeutics, Ocuphire Pharma, TearClear, Peregrine Ophthalmic, and others.

These companies are actively pursuing R&D investments, regulatory approvals, licensing deals, and strategic collaborations to strengthen market presence and expand therapeutic portfolios.

Glaucoma Market Outlook Through 2034

DelveInsight forecasts sustained growth in the glaucoma market through 2034, driven by:

* Increasing adoption of long-acting therapies
* Expansion of diagnosed patient populations
* Technological integration across pharmaceuticals and devices
* Growing investment interest in ophthalmology innovation

Emerging therapies such as NCX-470, DURYSTA, and iDose TR are expected to achieve rapid uptake, reshaping treatment algorithms and competitive positioning.

Discover trends, opportunities, and company strategies shaping the Glaucoma treatment landscape through 2034 - [https://www.delveinsight.com/sample-request/glaucoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

About DelveInsight

DelveInsight is a leading life science market research and business consulting firm, specializing in syndicated market reports, epidemiology forecasting, competitive intelligence, and customized strategic solutions. With deep domain expertise across pharmaceuticals, biotech, and medical devices, DelveInsight empowers stakeholders to make data-driven decisions and capitalize on emerging market opportunities.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=glaucoma-market-forecast-2034-usd-4073-million-market-size-30-companies-and-15-emerging-therapies-shaping-growth-estimates-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.